Following reports of adverse events, the FDA has issued an alert to healthcare providers, compounders and patients regarding dosing errors associated with compounded injectable semaglutide products. Dosing errors have reportedly resulted from patients measuring and self-administering incorrect doses and healthcare providers miscalculating doses of the drug. According to the adverse event reports, many of the patients who received vials of compounded semaglutide lacked experience with sel...